|Bid||0.00 x N/A|
|Ask||0.00 x N/A|
|Day's range||146.93 - 147.40|
|52-week range||146.93 - 147.40|
|Beta (5Y monthly)||0.45|
|PE ratio (TTM)||0.21|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
The Federal Trade Commission (FTC) issued warning letters to several pharmaceutical companies, including AbbVie (ABBV) AstraZeneca (AZN), and Teva (TEVA), over excessive patenting of medications as Medicare negotiates drug costs with the pharma industry. Yahoo Finance Health Reporter Anjalee Khemlani explains the Biden administration's ideas to license patents to lower drug costs for patients. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.
AbbVie (ABBV) announced it is acquiring neuroscience drug developer Cerevel Therapeutics (CERE) for $45.00 per share, putting the deal value at about $8.7 billion. AbbVie Chairman and CEO Richard Gonzalez said in the announcement that the combined portfolios will present a "significant growth opportunity well into the next decade." The deal comes about a week after AbbVie announced it was acquiring cancer drugmaker ImmunoGen (IMGN) for just over $10 billion. Yahoo Finance Healthcare Reporter Anjalee Khemlani breaks down the deal. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.
Shares of ImmunoGen (IMGN), a biotechnology company focused on cancer treatments, surged Thursday afternoon on news that pharmaceutical giant AbbVie (ABBV) plans to acquire the company in a deal valued around $10 billion. Yahoo Finance's Diane King Hall and Josh Lipton break down the details of the deal. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.